Regeneron Pharmaceuticals Stock Forecast, Price & News

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Regeneron Pharmaceuticals stock.
View analyst ratings for Regeneron Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Regeneron Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Regeneron Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Regeneron Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totaling 1,840,000 shares, an increase of 30.5% from the June 30th total of 1,410,000 shares. Based on an average trading volume of 755,700 shares, the short-interest ratio is presently 2.4 days. Approximately 1.8% of the shares of the company are sold short.
View Regeneron Pharmaceuticals' Short Interest.

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals will be holding an earnings conference call on Thursday, August 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings data on Thursday, May, 6th. The biopharmaceutical company reported $9.89 EPS for the quarter, topping analysts' consensus estimates of $7.78 by $2.11. The biopharmaceutical company had revenue of $2.53 billion for the quarter, compared to analyst estimates of $2.69 billion. Regeneron Pharmaceuticals had a trailing twelve-month return on equity of 35.43% and a net margin of 43.53%. Regeneron Pharmaceuticals's quarterly revenue was up 38.3% compared to the same quarter last year. During the same period in the previous year, the business earned $6.60 earnings per share.
View Regeneron Pharmaceuticals' earnings history.

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REGN shares have increased by 25.0% and is now trading at $581.01.
View which stocks have been most impacted by COVID-19.

Regeneron Pharmaceuticals announced that its Board of Directors has initiated a share buyback plan on Tuesday, November 5th 2019, which allows the company to repurchase $1,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 2.9% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company's leadership believes its shares are undervalued.

16 brokers have issued 12-month price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $495.00 to $800.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $659.06 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price.
View analysts' price targets for Regeneron Pharmaceuticals or view top-rated stocks among Wall Street analysts.

423 employees have rated Regeneron Pharmaceuticals CEO Leonard S. Schleifer on Glassdoor.com. Leonard S. Schleifer has an approval rating of 87% among Regeneron Pharmaceuticals' employees.

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Halozyme Therapeutics (HALO).
View all of REGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), The Walt Disney (DIS), Micron Technology (MU), Advanced Micro Devices (AMD) and salesforce.com (CRM).

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Regeneron Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Oregon Public Employees Retirement Fund (0.02%), State of Alaska Department of Revenue (0.02%), Greenwich Wealth Management LLC (0.02%), IFM Investors Pty Ltd (0.01%), Traynor Capital Management Inc. (0.01%) and Prentiss Smith & Co. Inc. (0.01%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Arthur F Ryan, Bonnie L Bassler, Christopher R Fenimore, George L Sing, George Yancopoulos, Huda Y Zoghbi, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Marion Mccourt, Michael S Brown, Neil Stahl, P Roy Vagelos, Plew Daniel P Van, Robert E Landry and Sanofi.
View institutional ownership trends for Regeneron Pharmaceuticals.

REGN stock was sold by a variety of institutional investors in the last quarter, including Vancity Investment Management Ltd, State of Alaska Department of Revenue, Oregon Public Employees Retirement Fund, Boyd Watterson Asset Management LLC OH, Prentiss Smith & Co. Inc., New England Research & Management Inc., Veracity Capital LLC, and Compagnie Lombard Odier SCmA. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Arthur F Ryan, George L Sing, George Yancopoulos, Joseph J Larosa, Joseph L Goldstein, Marion Mccourt, Michael S Brown, P Roy Vagelos, Plew Daniel P Van, and Robert E Landry.
View insider buying and selling activity for Regeneron Pharmaceuticals or view top insider-selling stocks.

REGN stock was bought by a variety of institutional investors in the last quarter, including Fulton Bank N.A., IFM Investors Pty Ltd, Marshall Financial Group LLC, Pflug Koory LLC, Harel Insurance Investments & Financial Services Ltd., CHICAGO TRUST Co NA, Traynor Capital Management Inc., and Seven Springs Wealth Group LLC.
View insider buying and selling activity for Regeneron Pharmaceuticals or or view top insider-buying stocks.

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REGN stock can currently be purchased for approximately $581.01.

Regeneron Pharmaceuticals has a market capitalization of $61.90 billion and generates $8.50 billion in revenue each year. The biopharmaceutical company earns $3.51 billion in net income (profit) each year or $28.66 on an earnings per share basis.

Regeneron Pharmaceuticals employs 9,123 workers across the globe.

The following companies are subsidiares of Regeneron Pharmaceuticals: Loop Road Holdings LLC, OSMR Holdings, OSMR International, Old Saw Mill Holdings LLC, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, Regeneron Canada Company, Regeneron Capital International B.V., Regeneron Genetics Center LLC, Regeneron GmbH, Regeneron Healthcare Solutions Inc., Regeneron International Holdings LLC, Regeneron International Limited, Regeneron Ireland Designated Activity Company, Regeneron Ireland Holdings Unlimited Company, Regeneron NL B.V., Regeneron Spain S.L.U., Regeneron UK Limited, and Rockwood Road Holdings LLC.

Regeneron Pharmaceuticals was founded in 1988.

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

Regeneron Pharmaceuticals is headquartered at 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591.

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]